Astellas Pharma Unspadr Stock Current Valuation
| YPHA Stock | EUR 9.45 0.10 1.07% |
Valuation analysis of ASTELLAS PHARMA UNSPADR helps investors to measure ASTELLAS PHARMA's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that ASTELLAS PHARMA's price fluctuation is not too volatile at this time. Calculation of the real value of ASTELLAS PHARMA UNSPADR is based on 3 months time horizon. Increasing ASTELLAS PHARMA's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the ASTELLAS stock is determined by what a typical buyer is willing to pay for full or partial control of ASTELLAS PHARMA UNSPADR. Since ASTELLAS PHARMA is currently traded on the exchange, buyers and sellers on that exchange determine the market value of ASTELLAS Stock. However, ASTELLAS PHARMA's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 9.45 | Real 8.21 | Hype 9.35 | Naive 9.35 |
The real value of ASTELLAS Stock, also known as its intrinsic value, is the underlying worth of ASTELLAS PHARMA UNSPADR Company, which is reflected in its stock price. It is based on ASTELLAS PHARMA's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of ASTELLAS PHARMA's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of ASTELLAS PHARMA UNSPADR helps investors to forecast how ASTELLAS stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of ASTELLAS PHARMA more accurately as focusing exclusively on ASTELLAS PHARMA's fundamentals will not take into account other important factors: ASTELLAS PHARMA UNSPADR Company Current Valuation Analysis
ASTELLAS PHARMA's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, ASTELLAS PHARMA UNSPADR has a Current Valuation of 0.0. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturers—General (which currently averages 0.0) industry. The current valuation for all Germany stocks is 100.0% higher than that of the company.
ASTELLAS Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ASTELLAS PHARMA's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ASTELLAS PHARMA could also be used in its relative valuation, which is a method of valuing ASTELLAS PHARMA by comparing valuation metrics of similar companies.ASTELLAS PHARMA is currently under evaluation in current valuation category among its peers.
ASTELLAS Fundamentals
| Return On Equity | 0.0971 | |||
| Return On Asset | 0.0635 | |||
| Profit Margin | 0.11 % | |||
| Operating Margin | 0.17 % | |||
| Shares Outstanding | 1.83 B | |||
| Price To Earning | 28.51 X | |||
| Revenue | 1.41 T | |||
| Gross Profit | 1.04 T | |||
| EBITDA | 348.55 B | |||
| Net Income | 100.86 B | |||
| Cash And Equivalents | 305.99 B | |||
| Cash Per Share | 165.15 X | |||
| Total Debt | 308 M | |||
| Current Ratio | 1.49 X | |||
| Book Value Per Share | 905.03 X | |||
| Cash Flow From Operations | 325.33 B | |||
| Earnings Per Share | 0.57 X | |||
| Number Of Employees | 14.52 K | |||
| Beta | 0.51 | |||
| Market Capitalization | 24.49 B | |||
| Z Score | 47.4 | |||
| Annual Yield | 0.03 % | |||
| Last Dividend Paid | 55.0 |
About ASTELLAS PHARMA Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ASTELLAS PHARMA UNSPADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ASTELLAS PHARMA using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ASTELLAS PHARMA UNSPADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in ASTELLAS Stock
ASTELLAS PHARMA financial ratios help investors to determine whether ASTELLAS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ASTELLAS with respect to the benefits of owning ASTELLAS PHARMA security.